Market Overview

UPDATE: Stifel Nicolaus Downgrades Zogenix to Hold Following FDA Panel

Related ZGNX
Zohydro Gains Massachusetts Approval, Acts As Minor Catalyst For Zogenix
Zogenix Announces Departure of Chief Commercial Officer, Scott Shively

Stifel Nicolaus reduced its rating on Zogenix (NASDAQ: ZGNX) from Buy to Hold and removed its $6 price target.

Stifel Nicolaus said, "The FDA Advisory Committee for Zohydro ER (single-entity hydrocodone for moderate-severe chronic pain) voted 11-2 (one abstention) against approval, highlighting concern about the opioid abuse epidemic by adding yet another non tamper-resistant, high-dose opioid. … [I]ncomplete information about how to limit the addressable population, concern regarding REMS implementation, and lack of tamper-resistance were key sticking points. Although FDA may still approve Zohydro given its legal/regulatory mandate (PDUFA 3/1/13), we are downgrading Zogenix given increased risk on its key growth driver."

Zogenix closed at $2.36 on Friday.

Posted-In: Stifel NicolausAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (ZGNX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters